ClinicalTrials.gg
RecruitingNCT07583784HERO-AF-AMIUpdated Sep 2, 2026

Abbreviated Antithrombotic Therapy After PCI in Patients With AF and AMI

An interventional study of DAT (DOAC+clopidogrel) and DOAC monotherapy in Myocardial Infarction (MI), ST-Segment Elevation Myocardial Infarction(STEMI) and NSTEMI - Non-ST-Segment Elevation Myocardial Infarction, sponsored by Chonnam National University Hospital. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Chonnam National University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
860
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Myocardial Infarction by Chonnam National University Hospital — 7 open to participants now, 8 under way, none of them phase 3. Myocardial Infarction · Chonnam National University Hospital.

Planned enrollment
6th of 11
860 · median 860
Started
2026
with 2 others
No phase
9 of 12
6 open now
Registered
10th of 12
by date

Among the 12 studies in Myocardial Infarction by Chonnam National University Hospital, this one is the 6th largest by planned enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2026, is one of 9 with no phase, and was the 10th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

7 of the 12 studies in Myocardial Infarction by Chonnam National University Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Myocardial Infarction by Chonnam National University Hospital, or all of them as a file.
02

Study summary

The aim of the study is to compare clinical outcomes between direct oral anticoagulant (DOAC) monotherapy versus dual antithrombotic therapy (DOAC plus clopidogrel) in patients with atrial fibrillation and acute myocardial infarction after percutaneous coronary intervention (PCI).

Read the detailed description

Advancements in device technologies for PCI and adjunct pharmacotherapy have recently shifted research focus toward balancing bleeding risk reduction with the management of ischemic events through novel antithrombotic strategies. These trends are particularly relevant for patients with atrial fibrillation (AF) who require lifelong oral anticoagulation to prevent embolic events. Traditionally, the combination of vitamin K antagonists (such as warfarin) with antiplatelet agents has been regarded as the standard approach to mitigate ischemic risk following PCI in patients with AF. However, previous studies have consistently demonstrated that dual antithrombotic therapy (DAT) utilizing direct oral anticoagulants (DOACs) results in reduced bleeding complications compared to triple antithrombotic therapy based on warfarin.

For long-term maintenance, DOAC monotherapy is recommended, as a Class I, after 6 to 12 months post-PCI for patients with stable coronary artery disease (CAD) and AF. Recent randomized clinical trials corroborate these recommendations. The AFIRE (Atrial Fibrillation and Ischemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease) study showed that rivaroxaban monotherapy was non-inferior to DAT in terms of both bleeding and ischemic outcomes. The EPIC-CAD (Edoxaban versus Edoxaban with Antiplatelet Agent in Patients with Atrial Fibrillation and Chronic Stable Coronary Artery Disease) trial further extended this evidence, indicating that edoxaban monotherapy reduced the risk of net adverse clinical events (NACE)-a composite of death, myocardial infarction, stroke, systemic embolism, unplanned urgent revascularization, and major or clinically relevant nonmajor bleeding-compared to DAT. Recently, the ADAPT AF-DES (Appropriate Duration of Antiplatelet and Thrombotic Strategy after 12 Months in Patients with Atrial Fibrillation Treated with Drug-Eluting Stents) trial demonstrated that DOAC monotherapy was non-inferior, and even superior, to combination therapy with a DOAC and clopidogrel regarding NACE reduction in patients with AF and stable CAD following PCI. However, these studies have primarily focused on patients with stable CAD who inherently have a lower ischemic risk. Despite limited evidence supporting DOAC monotherapy as a maintenance strategy for acute myocardial infarction (AMI) patients, recent guidelines have also recommended this approach after 1 year (Class I) or 6 months (Class IIB) following PCI in AMI setting. Furthermore, in real-world data, the DAT remained effective in reducing ischemic events without increasing the risk of bleeding compared with DOAC monotherapy. Additionally, DOAC monotherapy showed a lower risk of NACE at 3 years, but was not significantly effective at 1 year after PCI.

To address this critical evidence gap in clinical practice, we have developed the Heart-team for Evidence-based Revascularization: Abbreviated Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation and Acute Myocardial Infarction (HERO-AF-AMI). This study aims to evaluate the impact of DOAC monotherapy compared to DAT (DOAC plus clopidogrel) in patients with AF and AMI undergoing PCI.

03

Conditions studied

  • Myocardial Infarction (MI)
  • ST-Segment Elevation Myocardial Infarction(STEMI)
  • NSTEMI - Non-ST-Segment Elevation Myocardial Infarction
  • AF - Atrial Fibrillation

Keywords

  • AF
  • Myocardial infarction
  • STEMI
  • NSTEMI
  • DOAC
  • NOAC
  • OAC alone
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged 19 years old
  2. Patients with AF and CHA2DS2-VA score ≥2.
  3. ST-segment elevation myocardial infarction (STEMI) or Non-ST-segment elevation myocardial infarction (NSTEMI)

    • STEMI: ST-segment elevation ≥0.1 mV in ≥2 contiguous leads or documented newly developed left bundle-branch block.12
    • NSTEMI: NSTEMI is defined as a combination of criteria with mandated elevation of a cardiac biomarker, preferably high-sensitive cardiac troponin with at least one value above 99th percentile of the upper reference limit and at least one of the following:12

      1. Symptoms of ischemia.
      2. New or presumed new significant ST-T wave changes
      3. Development of pathological Q waves on electrocardiography.
      4. Imaging evidence of new or presumed new loss of viable myocardium or regional wall motion abnormality.
      5. Intracoronary thrombus detected on angiography.
  4. Patients underwent PCI for AMI (STEMI or NSTEMI) at least 6 months before enrollment.

Exclusion criteria

Exclusion Criteria:

  1. Patients for use of DOACs or clopidogrel
  2. Mechanical prosthetic valve or moderate-to-severe mitral stenosis requiring vitamin K antagonist
  3. Planned cardiac surgery within 1 year after randomization
  4. Patients with severe thrombocytopenia or coagulopathy
  5. Liver cirrhosis or severe hepatic dysfunction
  6. Advanced chronic kidney disease ( \<15 ml/min/1.73 m2) or on dialysis
  7. Prior history of intracranial hemorrhage
  8. Coexisting conditions related to high risk of life-threatening bleeding
  9. Pregnancy or breast feeding
  10. Non-cardiac co-morbid conditions are present with \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment)
  11. Unwillingness or inability to comply with the procedures described in this protocol.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
860 participants (estimated)

Study arms

  • Active comparator
    DAT (DOAC+clopidogrel) group

    Patients who were indicated lifelong oral anticoagulation for AF with a CHA2DS2-VA score equal to or greater than 2 points, and treated AMI with PCI are candidates. After 6 months of index procedure, the patients will be screened for inclusion and exclusion criteria, and eligible patients will be randomized into either the DOAC monotherapy group or the DAT group. Patients allocated to the DAT group receive either apixaban 5 mg twice daily, edoxaban 60 mg once daily, or rivaroxaban 15 mg once daily with clopidogrel 75 mg once daily.

    Drug: DAT (DOAC+clopidogrel)

  • Experimental
    DOAC monotherapy group

    Patients who were indicated lifelong oral anticoagulation for AF with a CHA2DS2-VA score equal to or greater than 2 points, and treated AMI with PCI are candidates. After 6 months of index procedure, the patients will be screened for inclusion and exclusion criteria, and eligible patients will be randomized into either the DOAC monotherapy group or the DAT group. Patients allocated to the DOAC monotherapy group receive either apixaban 5 mg twice daily, edoxaban 60 mg once daily, or rivaroxaban 20 mg once daily.

    Drug: DOAC monotherapy

Interventions

  • DrugDAT (DOAC+clopidogrel)

    Patients allocated to the DAT group receive either apixaban 5 mg twice daily, edoxaban 60 mg once daily, or rivaroxaban 15 mg once daily with clopidogrel 75 mg once daily.

  • DrugDOAC monotherapy

    Patients allocated to the DOAC monotherapy group receive either apixaban 5 mg twice daily, edoxaban 60 mg once daily, or rivaroxaban 20 mg once daily.

06

What researchers measure

Primary outcomes

  1. NACE (net adverse clinical events)

    a composite of death, non-fatal MI, stroke, systemic embolization, unplanned revascularization, stent thrombosis, major or clinically relevant non-major bleeding by ISTH

    Time frame: 1 year after the last patient enrollment

Secondary outcomes

  1. Rate of major bleeding by ISTH

    major bleeding events by ISTH definition

    Time frame: 1 year after the last patient enrollment

  2. Rate of MACCE (major adverse cardiac and cerebrovascular event)

    a composite of cardiovascular death, non-fatal MI, ischemic stroke, systemic embolization, unplanned revascularization, and stent thrombosis

    Time frame: 1 year after the last patient enrollment

  3. All-cause death

    all-cause death

    Time frame: 1 year after the last patient enrollment

  4. Cardiovascular death

    cardiovascular death

    Time frame: 1 year after the last patient enrollment

  5. Rate of non-fatal MI

    non-fatal MI, defined by Fourth Universal definition of MI

    Time frame: 1 year after the last patient enrollment

  6. Rate of ischemic stroke

    ischemic stroke

    Time frame: 1 year after the last patient enrollment

  7. Rate of systemic embolization

    systemic embolization

    Time frame: 1 year after the last patient enrollment

  8. Rate of unplanned revascularization

    unplanned revascularization (clinically-driven)

    Time frame: 1 year after the last patient enrollment

  9. Rate of definite stent thrombosis

    definite stent thrombosis, defined by Academic Research Consortium (ARC) II consensus

    Time frame: 1 year after the last patient enrollment

  10. Rate of cardiovascular death or non-fatal MI

    a composite of cardiovascular death or non-fatal MI

    Time frame: 1 year after the last patient enrollment

  11. Rate of all-cause death, non-fatal MI, stroke, systemic embolization, stent thrombosis, or ISTH major bleeding

    a composite of all-cause death, non-fatal MI, stroke, systemic embolization, stent thrombosis, or ISTH major bleeding

    Time frame: 1 year after the last patient enrollment

  12. Rate of major or clinically relevant non-major bleeding by ISTH

    major or clinically relevant non-major bleeding by ISTH

    Time frame: 1 year after the last patient enrollment

  13. Rate of fatal bleeding by ISTH

    fatal bleeding by ISTH

    Time frame: 1 year after the last patient enrollment

  14. Rate of clinically relevant non-major bleeding by ISTH

    clinically relevant non-major bleeding by ISTH

    Time frame: 1 year after the last patient enrollment

  15. Rate of any bleeding by ISTH

    any bleeding by ISTH

    Time frame: 1 year after the last patient enrollment

Other outcomes

  1. Blood pressure control status

    mean value, variability, and control rate of blood pressure

    Time frame: 1 year after the last patient enrollment

  2. AF rhythm event

    AF episode frequency and lasting time

    Time frame: 1 year after the last patient enrollment

  3. AF burden (%)

    AF burden (%)

    Time frame: 1 year after the last patient enrollment

07

Study locations

1 of 1 sites recruiting
  • Chonnam National University Hospital
    Gwangju, Gwangju 61469, South Korea
    Recruiting
    • Young Joon Hong, MD, PhD · Contacthyj200@hanmail.net · 82-62-220-6246
    • Seung Hun Lee, MD, PhD · Contact
    • Young Joon Hong, MD, PhD · Principal investigator
    • Seung Hun Lee, MD, PhD · Sub investigator
    • Joon Ho Ahn, MD, PhD · Sub investigator
    • Seok Oh, MD, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — After publication of main paper, de-identified data will be shared upon reasonable requests after discussion by Executive Committee.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After publication of main paper.

Access criteria: Executive Committee will discuss to share the de-identified data upon reasonable requests.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2031, 64 months after the start.

Of 322 non-industry interventional studies with no phase under Myocardial Infarction, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's planned 64 months is above that.

Counting every sponsor, half of 355 studies reached it within 34 months; a quarter within 15 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2026
First posted
May 13, 2026
StartActual
Aug 26, 2026
Primary completionEst.
Dec 31, 2031
CompletionEst.
Dec 31, 2032
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07583784
Lead sponsor
Chonnam National University Hospital
Responsible party
Young Joon Hong (Professor, Chonnam National University Hospital) — Principal investigator
First posted
May 13, 2026
Start date
Aug 26, 2026
Primary completion
Dec 31, 2031 (estimated)
Completion
Dec 31, 2032 (estimated)
Last update
Sep 2, 2026

Study contacts

Seung Hun Lee, MD, PhD
Contact
lsh8602@naver.com
82-2-220-6246
Joon Ho Ahn, MD, PhD
Contact
yhbky@naver.com
82-2-220-6246
Young Joon Hong, MD, PhD
study chair · Chonnam National University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion